
Linda Hammerich

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7447679/publications.pdf Version: 2024-02-01



LINDA HAMMERICH

#	Article	IF	CITATIONS
1	Ferroptosis in Cancer Immunotherapy—Implications for Hepatocellular Carcinoma. Immuno, 2022, 2, 185-217.	0.6	3
2	Combination of C-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF. Journal of Hepatology, 2022, 77, 1325-1338.	1.8	31
3	Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions. Neuroendocrinology, 2021, 111, 217-236.	1.2	17
4	From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis. International Journal of Molecular Sciences, 2021, 22, 1492.	1.8	16
5	In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 650486.	2.2	26
6	The Role of miRNA in the Pathophysiology of Neuroendocrine Tumors. International Journal of Molecular Sciences, 2021, 22, 8569.	1.8	8
7	Elevated Flt3L Predicts Long-Term Survival in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers, 2021, 13, 4463.	1.7	2
8	Immune Regulatory 1 Cells: A Novel and Potent Subset of Human T Regulatory Cells. Frontiers in Immunology, 2021, 12, 790775.	2.2	0
9	Dendritic Cell and T Cell Crosstalk in Liver Fibrogenesis and Hepatocarcinogenesis: Implications for Prevention and Therapy of Liver Cancer. International Journal of Molecular Sciences, 2020, 21, 7378.	1.8	62
10	Antitumor T-cell Homeostatic Activation Is Uncoupled from Homeostatic Inhibition by Checkpoint Blockade. Cancer Discovery, 2019, 9, 1520-1537.	7.7	12
11	Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nature Medicine, 2019, 25, 814-824.	15.2	293
12	Natural pattern-recognition-receptor agonists as adjuvants for in situ vaccination lymphoma immunotherapy Journal of Clinical Oncology, 2018, 36, 123-123.	0.8	1
13	Improving efficacy of PD-1 blockade in unresponsive lymphoma tumors with in situ vaccination through induction of a highly efficient cross-presenting dendritic cell subset Journal of Clinical Oncology, 2018, 36, 76-76.	0.8	0
14	<i>In situ</i> vaccination for the treatment of cancer. Immunotherapy, 2016, 8, 315-330.	1.0	71
15	Combining In Situ Vaccination with Immune Checkpoint Blockade Induces Long-Term Regression of Lymphoma Tumors. Blood, 2016, 128, 465-465.	0.6	2
16	Converting a tumor from checkpoint blockade-resistant to checkpoint blockade-sensitive: Immunotransplant for aggressive lymphoma Journal of Clinical Oncology, 2016, 34, e14538-e14538.	0.8	0
17	Natural pattern-recognition-receptor agonists in prophylactic vaccines for in situ vaccination of lymphoma Journal of Clinical Oncology, 2016, 34, e14516-e14516.	0.8	0
18	Flt3L-based in situ vaccination for the treatment of lymphoma Journal of Clinical Oncology, 2016, 34, e19040-e19040.	0.8	0

LINDA HAMMERICH

#	Article	IF	CITATIONS
19	Lymphoma: Immune Evasion Strategies. Cancers, 2015, 7, 736-762.	1.7	35
20	Emerging roles of myeloid derived suppressor cells in hepatic inflammation and fibrosis. World Journal of Gastrointestinal Pathophysiology, 2015, 6, 43.	0.5	41
21	Natural Toll-like Receptor Agonists for in Situ Vaccination Lymphoma Immunotherapy. Blood, 2015, 126, 4002-4002.	0.6	Ο
22	Interleukins in chronic liver disease: lessons learned from experimental mouse models. Clinical and Experimental Gastroenterology, 2014, 7, 297.	1.0	99
23	Role of gamma-delta T cells in liver inflammation and fibrosis. World Journal of Gastrointestinal Pathophysiology, 2014, 5, 107.	0.5	61
24	Chemokine Receptor CXCR6-Dependent Hepatic NK T Cell Accumulation Promotes Inflammation and Liver Fibrosis. Journal of Immunology, 2013, 190, 5226-5236.	0.4	219
25	Eat more carrots? Dampening cell death in ethanol-induced liver fibrosis by β-carotene. Hepatobiliary Surgery and Nutrition, 2013, 2, 248-51.	0.7	1
26	Role of IL-17 and Th17 Cells in Liver Diseases. Clinical and Developmental Immunology, 2011, 2011, 1-12.	3.3	202